<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03717350</url>
  </required_header>
  <id_info>
    <org_study_id>SUPERIOR</org_study_id>
    <nct_id>NCT03717350</nct_id>
  </id_info>
  <brief_title>suPAR to Guide Antibiotics in Emergency Department</brief_title>
  <official_title>A suPAR Guided Double-blind Randomized Clinical Trial of Initiation of Antibiotics for Presumed Infection at the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Institute for the Study of Sepsis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic Institute for the Study of Sepsis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to evaluate suPAR - guided medical intervention, consisting&#xD;
      of early antibiotic administration at the emergency room for presumed infection and sepsis&#xD;
      and evaluate the impact of this intervention to the patients' final outcome. Since the&#xD;
      traditionally used biomarkers (PCT, CRP) and scores (SOFA score) for early recognition of&#xD;
      severity of infection fail to achieve maximum accuracy in all cases, suPAR levels are&#xD;
      assessed as a probably better prognostic rule for early recognition of severe infections. The&#xD;
      primary study endpoint will be the comparative efficacy of the early suPAR-guided&#xD;
      administration of antibiotics versus standard practice on 28-day mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sepsis is among the leading causes of death worldwide. It is well-perceived that early&#xD;
      recognition of sepsis is the mainstay of treatment. Recently it has been proposed that the&#xD;
      quick sequential organ fialure assessment (qSOFA) score can be used as a screening tool in&#xD;
      the emergency department (ED) to triage patients with high-risk of death; patients scoring&#xD;
      positive at least two of the three signs of qSOFA are at a high-risk for death. However, this&#xD;
      is challenged since it may be the case that the risk of death is high even among patients&#xD;
      with only one sign of qSOFA.&#xD;
&#xD;
      Soluble urokinase plasminogen activator receptor (suPAR), the soluble form of the membrane&#xD;
      bound receptor (uPAR), is a recently known glycoprotein involved in inflammation. uPAR is&#xD;
      expressed on various immune cells (neutrophils, lymphocytes, monocytes, macrophages) and is&#xD;
      cleaved from their surface after an inflammatory stimuli to enhance chemotaxis and cell&#xD;
      migration. Increased suPAR blood levels mirror the degree of activation of the immune system&#xD;
      by different antigenic stimuli including diverse neoplastic and infectious agents and other&#xD;
      inflammation-mediated diseases. SuPAR levels generally correlate to the severity of the&#xD;
      disease.&#xD;
&#xD;
      It has been shown that suPAR blood levels have low diagnostic value (cannot discriminate&#xD;
      between bacterial, viral or parasitic infection, Gram (+) or Gram (-) bacteraemia. However,&#xD;
      they present superior prognostic value as compared with single parameters of inflammation and&#xD;
      organ dysfunction (like C-reactive protein (CRP) and procalcitonin (PCT) in critically ill&#xD;
      patients, and suPAR's prognostic value of death is even more enhanced when combined to other&#xD;
      biomarkers and physiological scores (e.g. Acute Physiology and Chronic Health&#xD;
      Evaluation-APACHE II).&#xD;
&#xD;
      Why choose suPAR as biomarker at emergency basis? Because, in contrast to many&#xD;
      pro-inflammatory cytokines, suPAR exhibits favorable properties due to its high stability in&#xD;
      serum samples and limited circadian changes in plasma concentrations. It also constitutes a&#xD;
      serum/plasma biomarker that is easily performed on-site and provides information within one&#xD;
      hour after sampling21, 22.&#xD;
&#xD;
      Unpublished data of the Hellenic Sepsis Study Group (HSSG) suggest that among patients with&#xD;
      at least one sign of the qSOFA score, those with suPAR greater than 12 ng/ml are at a&#xD;
      substantial risk for death with mortality exceeding 30%. To this end, patients with suspicion&#xD;
      for an infection and with qSOFA 1 and suPAR greater than 12 ng/ml constitute a group of&#xD;
      patients requiring early intervention.&#xD;
&#xD;
      The aim of the current study is to evaluate suPAR - guided medical intervention, consisting&#xD;
      of early antibiotics' administration at the emergency room for presumed infection and sepsis&#xD;
      and evaluate the impact of this intervention to the patients' final outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Similar appearance of study drug of both arms</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of the applied intervention versus standard practice on the early worsening of the patient.</measure>
    <time_frame>1 day (24 hours)</time_frame>
    <description>The primary study endpoint will be the comparative efficacy of the applied intervention (meropenem versus standard practice on the early worsening of the patient. This is defined as any at least one point increase of the admission total SOFA score the first 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sepsis mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Comparative efficacy of the applied intervention on mortality for patients meeting the Sepsis-3 definition of sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term mortality</measure>
    <time_frame>7 days</time_frame>
    <description>Comparative efficacy of the applied intervention on 7-day mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term mortality 1</measure>
    <time_frame>60 days</time_frame>
    <description>Comparative efficacy of the applied intervention on 60-day mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term mortality 2</measure>
    <time_frame>90 days</time_frame>
    <description>Comparative efficacy of the applied intervention on 90-day mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection resolution</measure>
    <time_frame>90 days</time_frame>
    <description>Effect of the intervention on the time to infection resolution. This time point is limited for patients who will eventually be diagnosed of a specific infectious diseases making them eligible for the study and it is defined as the time point when all clinical signs of the infection are cleared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of initial treatment</measure>
    <time_frame>28 days</time_frame>
    <description>Comparative efficacy of the applied intervention on the need to change antibiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>90 days</time_frame>
    <description>Comparative efficacy of the applied intervention on the duration of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of new infections</measure>
    <time_frame>90 days</time_frame>
    <description>Comparative efficacy of the applied intervention on the rate of new infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The early worsening of the patient</measure>
    <time_frame>1 day (24 hours)</time_frame>
    <description>The early worsening of the patient defined as for the primary endpoint but analyzed separately per quartile of the total SOFA score of the patient population</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100ml of sodium chloride 0.9% within 15 minutes intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously administered once</description>
    <arm_group_label>Antibiotic</arm_group_label>
    <other_name>Carbapenem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100ml of sodium chloride 0.9% within 15 minutes intravenously once</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Diluent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent provided by the patient or by their legal representative in&#xD;
             case of patients unable to consent&#xD;
&#xD;
          2. Age equal to or above 18 years&#xD;
&#xD;
          3. Male or female gender&#xD;
&#xD;
          4. Clinical suspicion of infection&#xD;
&#xD;
          5. qSOFA equal to 1 point&#xD;
&#xD;
          6. suPAR blood level equal or above 12 ng/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Denial to consent&#xD;
&#xD;
          2. Patients with 2 or 3 qSOFA signs&#xD;
&#xD;
          3. Pregnancy (confirmed by blood or urinary pregnancy test) for female patients of&#xD;
             reproductive age&#xD;
&#xD;
          4. Organ transplantation&#xD;
&#xD;
          5. Fully-blown sepsis with overt failing organs necessitating immediate resuscitation as&#xD;
             defined by the attending physicians&#xD;
&#xD;
          6. Do not resuscitate decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evangelos Giamarellos-Bourboulis, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Attikon Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evangelos J Giamarellos-Bourboulis, MD, PhD</last_name>
    <phone>+306945521800</phone>
    <email>egiamarel@med.uoa.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charambos Gogos, MD, PhD</last_name>
    <phone>+306944799784</phone>
    <email>egogos@med.upatras.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>4th Department of Internal Medicine, ATTIKON University Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonios Papadopoulos, MD, PhD</last_name>
      <phone>+306977302400</phone>
      <email>antpapa1@otenet.gr</email>
    </contact>
    <contact_backup>
      <last_name>Evdoxia Kyriazopoulou, MD, PhD</last_name>
      <phone>+302105832563</phone>
      <email>ekyr@med.uoa.gr</email>
    </contact_backup>
    <investigator>
      <last_name>Antonios Papadopoulos, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikolaos Antonakos, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria-Evangelia Adami, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>1st Department of Internal Medicine of G. GENNIMATAS General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Adamis, MD</last_name>
      <phone>2107768534</phone>
      <email>adamismd@otenet.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>3rd Department of Internal Medicine at SOTIRIA General Hospital of Chest Diseases of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Garyfallia Poulakou, MD, PhD</last_name>
      <phone>2107763400</phone>
      <email>gpoulakou@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Εmergency Department of Sismanogleion Athens General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>15126</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vassileios Kaldis, MD</last_name>
      <phone>2132058 841</phone>
      <email>vkaldis@yahoo.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Patras University Hospital</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charalambos Gogos, MD, PhD</last_name>
      <phone>+306944799784</phone>
      <email>cgogos@med.upatras.gr</email>
    </contact>
    <contact_backup>
      <last_name>Karolina Akinosoglou, MD, PhD</last_name>
      <phone>++306977762897</phone>
      <email>akin@upatras.gr</email>
    </contact_backup>
    <investigator>
      <last_name>Charalambos Gogos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karolina Akinosoglou, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ann-Liz Delastic, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Giamarellos-Bourboulis EJ, Tsaganos T, Tsangaris I, Lada M, Routsi C, Sinapidis D, Koupetori M, Bristianou M, Adamis G, Mandragos K, Dalekos GN, Kritselis I, Giannikopoulos G, Koutelidakis I, Pavlaki M, Antoniadou E, Vlachogiannis G, Koulouras V, Prekates A, Dimopoulos G, Koutsoukou A, Pnevmatikos I, Ioakeimidou A, Kotanidou A, Orfanos SE, Armaganidis A, Gogos C; Hellenic Sepsis Study Group. Validation of the new Sepsis-3 definitions: proposal for improvement in early risk identification. Clin Microbiol Infect. 2017 Feb;23(2):104-109. doi: 10.1016/j.cmi.2016.11.003. Epub 2016 Nov 14.</citation>
    <PMID>27856268</PMID>
  </reference>
  <reference>
    <citation>Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, Savva A, Tsangaris I, Dimopoulou I, Mouktaroudi M, Raftogiannis M, Georgitsi M, Linnér A, Adamis G, Antonopoulou A, Apostolidou E, Chrisofos M, Katsenos C, Koutelidakis I, Kotzampassi K, Koratzanis G, Koupetori M, Kritselis I, Lymberopoulou K, Mandragos K, Marioli A, Sundén-Cullberg J, Mega A, Prekates A, Routsi C, Gogos C, Treutiger CJ, Armaganidis A, Dimopoulos G. Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Crit Care. 2012 Aug 8;16(4):R149. doi: 10.1186/cc11463.</citation>
    <PMID>22873681</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 20, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biomarkers</keyword>
  <keyword>suPAR</keyword>
  <keyword>outcome</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

